30HU-008
Starting at:
Starting at: $1,945.00
Starting at: $1,945.00
| SKU | Package Size | Price | Quantity | Add to Cart |
|---|---|---|---|---|
| 30HU-003 | Cryopreserved, 0.5-1.0 million cells/vial | Starting at: $1,945.00 |
Product Description
Parkinson’s Disease is a progressive neurodegenerative disorder that causes “motor” symptoms, including tremor, rigidity, bradykinesia, and postural instability, and “non-motor” symptoms, including depression, anxiety, and other cognitive problems [1].
Induced Pluripotent Stem Cell (iPSC) is a type of stem cells generated by reprogramming mature, specialized somatic cells into an embryonic-like pluripotent state [2]. iPSC exhibits large self-renewal and differentiation capability, which makes it a unique cell model for regenerative medicine [3]. iPSCs reprogrammed from Parkinson’s disease carriers can be differentiated into specific cell types, like dopaminergic neurons and motor neurons, enabling research for early diagnosis and treatments.
iXCells Biotechnologies is proud to offer human iPS cell lines derived from the human somatic cells (dermal fibroblasts) from patients with Parkinson’s Disease (PD). The pertinent donor information is available upon request ([email protected]). These iPS cells are established from single clones and expanded in feeder-free conditions. The Certificate of Analysis (CoA) is provided for each cell lot purchased. The cells have been characterized for the self-renewal and pluripotency markers (Figure 1). All the cells provided by iXCells are negative for mycoplasma, bacteria, yeast, fungi, HIV-1, HBV, and HCV.
Normal human iPS cell lines are also available as separate products (Cat# 30HU-002). Other currently available disease-specific iPS cell lines are derived from patients with Type 2 Diabetes (T2D; Cat#30HU-005), Alzheimer’s Disease (AD; Cat#30HU-008, Cat#30HU-009), Amyotrophic Lateral Sclerosis (ALS; Cat#30HU-004). More disease-specific iPS cell lines are in development. We also provide custom iPSC generation and iPSC differentiation services to meet your needs.
Figure 1. iXCells human iPS Cell Lines (Parkinson’s Disease) are characterized by immunostaining targeting Oct4, Nanog, TRA-1-60, and TRA-1-81. Cell nuclei are stained by DAPI (Blue).
Product Details
| Organism | Homo Sapiens, Human |
| Tissue Origin | Dermal fibroblast |
| Cell Type | iPSC |
| Disease | Parkinson’s Disease |
| Package Size | 0.5-1.0 x 106cells/vial |
| Growth Properties | Adherent |
| Product Format/Shipped | Cryopreserved |
| Storage | Liquid Nitrogen |
| Associated Media | Human iPSC Feeder-Free Growth Medium (Cat# MD-0019) |
[1] Sveinbjornsdottir, S. (2016). The clinical symptoms of Parkinson’s disease. Journal of neurochemistry, 139, 318-324.
[2] Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., Shibata, T., Kunisada, T., Takahashi, M., Takahashi, J., Saji, H., & Yamanaka, S. (2011). A more efficient method to generate integration-free human iPS cells. Nature methods, 8(5), 409–412.
[3] Medvedev, S. P., Shevchenko, A. I., & Zakian, S. M. (2010). Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine. Acta naturae, 2(2), 18–28.
FREQUENTLY BOUGHT TOGETHER - RECOMMENDED FOR YOU!
